Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

24 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

ImmunoGen Articles

US FDA approves Roche's late-stage breast cancer drug Kadcyla

25 February 2013

Licensing deals for Amgen/ImmunoGen and Shire/Arrowhead

20 December 2012

More highlights from ESMO Congress

2 October 2012

ImmunoGen IND for IMGN853 now active; IMGN529 trial commenced

17 April 2012

ImmunoGen inks ADC cancer deal with Lilly

21 December 2011

Sanofi pays $3 million milestone to ImmunoGen on start of SAR3419 Ph II testing; FDA accepts Aubagio filing

21 October 2011

ImmunoGen earns $2 million milestone from Bayer

16 June 2011

ImmunoGen collaborates with Novartis on cancer drugs for $45 million upfront, plus potential $200 million per target; updates financials

12 October 2010

Showing 1-8 of 8 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS